Sucampo Submits Lubiprostone Supplemental NDA For Irritable Bowel Syndrome
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is seeking approval of a lower 8 mcg dose of medication, which is already marketed in a 24 mcg formulation for chronic idiopathic constipation.
You may also be interested in...
Forest Teams Up With Microbia On IBS-C Agent Linaclotide
Firms plan to initiate Phase III studies in the second half of 2008.
Forest Teams Up With Microbia On IBS-C Agent Linaclotide
Firms plan to initiate Phase III studies in the second half of 2008.
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Novartis voluntarily suspends marketing of the irritable bowel syndrome medication due to cardiovascular events.